research LB1256 TRIV-509, a dual inhibitor of KLK5 and KLK7, rapidly improves barrier integrity and markers of epidermal differentiation in atopic dermatitis skin explants
TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
Search
for
Sort by
Research
420-450 / 1000+ resultsresearch A distinct cutaneous reaction to sorafenib and a multikinase inhibitor
Sorafenib can cause a unique skin reaction.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
research Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study.
The dutasteride nanoemulsion could improve hair loss treatment by enhancing drug penetration and retention in hair follicles.
research Detection of NUDT15 R139C variants and azathioprine utilization in patients with dermatologic conditions
research Finasteride/spironolactone
research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Comparative Efficacy Evaluation of Alopecia Areata Management with Janus Kinase Inhibitors in Children: Retrospective Cohort Study
Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
research Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?
Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
research Tofacitinib therapy for children with severe alopecia areata
Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
research The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
research Tofacitinib for the treatment of alopecia areata in preadolescent children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research Antroquinonol Exerts Immunosuppressive Effect on CD8+ T Cell Proliferation and Activation to Resist Depigmentation Induced by H2O2
Antroquinonol may help prevent skin depigmentation by suppressing certain immune cells.
research BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
research Pustular Eruption in a Patient Treated With Trametinib
Trametinib can cause skin issues, but they can often be managed without stopping the drug.
research Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.
research Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo
TS-13 effectively stops tumor growth and reduces chemotherapy side effects.
research 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia
Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
research Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with AIRE gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
Ruxolitinib helped a patient with alopecia areata regrow hair.
research Successful treatment of severe diffuse alopecia areata with abrocitinib
Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
research Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
research 17-Oximino-5-androsten-3β-yl esters: synthesis, antiproliferative activity, acute toxicity, and effect on serum androgen level
Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
research Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
research XEDAR activates the non-canonical NF-κB pathway
XEDAR triggers a specific signaling pathway in cells.
research New potential chemotherapy for ovarian cancer — Combined therapy with WP 631 and epothilone B
The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.